Filament Health Corp (FH) - Cash Flow Conversion Efficiency

Latest as of March 2025: -0.228x

Based on the latest financial reports, Filament Health Corp (FH) has a cash flow conversion efficiency ratio of -0.228x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-221.75K ≈ $-160.41K USD) by net assets (CA$974.38K ≈ $704.85K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Filament Health Corp (FH) total market value for the company's overall valuation and market capitalisation.

Filament Health Corp - Cash Flow Conversion Efficiency Trend (2020–2024)

This chart illustrates how Filament Health Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Filament Health Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Filament Health Corp ranked by their cash flow conversion efficiency. See Filament Health Corp debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.

Company Cash Flow Conversion Efficiency
Starbreeze AB (publ)
ST:STAR-A
-0.015x
Alliance Mining Corp
V:ALM
0.002x
SHF Holdings Inc
NASDAQ:SHFS
-406.953x
QURI-MAYU DEVELOPMENTS
F:JR9
-0.031x
Jaguar Animal Health Inc
NASDAQ:JAGX
-1.085x
Altech Batteries Ltd
AU:ATC
-0.199x
KINGS ENTERTAINMENT GROUP
F:L12
N/A
Therma Bright Inc
V:THRM
0.026x

Annual Cash Flow Conversion Efficiency for Filament Health Corp (2020–2024)

The table below shows the annual cash flow conversion efficiency of Filament Health Corp from 2020 to 2024. View FH stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CA$1.75 Million
≈ $1.26 Million
CA$-2.29 Million
≈ $-1.66 Million
-1.310x +22.06%
2023-12-31 CA$2.49 Million
≈ $1.80 Million
CA$-4.19 Million
≈ $-3.03 Million
-1.681x -38.80%
2022-12-31 CA$3.19 Million
≈ $2.31 Million
CA$-3.87 Million
≈ $-2.80 Million
-1.211x -270.68%
2021-12-31 CA$16.55 Million
≈ $11.97 Million
CA$-5.41 Million
≈ $-3.91 Million
-0.327x -247.81%
2020-12-31 CA$813.64K
≈ $588.58K
CA$-76.42K
≈ $-55.28K
-0.094x --

About Filament Health Corp

NEO:FH Canada
Market Cap
$1.89 Million
CA$2.62 Million CAD
Market Cap Rank
#30168 Global
#1497 in Canada
Share Price
CA$0.01
Change (1 day)
+0.00%
52-Week Range
CA$0.01 - CA$0.01
All Time High
CA$0.40
About

Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. The company's leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. It also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage. In addition, the company provide… Read more